Tokyo Medical and Dental University Hospital
Welcome,         Profile    Billing    Logout  
 3 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kinugasa, Yusuke
JCOG1801, NCT04288999: Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

Recruiting
3
110
Japan
Chemotherapy, CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV, Preoperative radiotherapy, Capecitabine plus radiotherapy, Procedure, Surgery
National Cancer Center Hospital East, Japan Clinical Oncology Group, Japan Agency for Medical Research and Development
Rectal Cancer Recurrent
08/25
10/28
Kanegane, Hirokazu
NCT06249997: An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS

Recruiting
3
3
Japan
Leniolisib
Pharming Technologies B.V., Laboratory Corporation of America, Axial Biotech, Inc, CMIC Co, Ltd. Japan
APDS Gene Mutation
01/25
03/25
NCT05438407 / 2022-001624-14: Pediatric Patients Aged 4 to 11 Years With APDS

Active, not recruiting
3
15
Europe, Japan, US
Leniolisib
Pharming Technologies B.V., CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
APDS
07/25
12/25
NCT05693129: Pediatric Patients Aged 1 to 6 Years with APDS

Recruiting
3
15
Europe, Japan, US
Leniolisib
Pharming Technologies B.V., CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
APDS
09/25
02/26
Denallo, Erica
NCT05693129: Pediatric Patients Aged 1 to 6 Years with APDS

Recruiting
3
15
Europe, Japan, US
Leniolisib
Pharming Technologies B.V., CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
APDS
09/25
02/26
B
EMERALD, NCT05001737 / 2021-001577-24: Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Active, not recruiting
3
41
Europe, Canada, Japan, US, RoW
Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO)
Swedish Orphan Biovitrum
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
06/24
09/25
NCT02506946: NAFLD in Adolescents and Young Adults With PCOS

Recruiting
N/A
80
US
Columbia University
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
09/25
09/25
NCT04965129: Supplementation of n-3 PUFA in the Modulation of Lean Mass in Patients With Lung Cancer Receiving a High-protein Diet

Recruiting
N/A
50
RoW
Placebo, Fish oil, Vital Fish
Universidade Federal do Rio de Janeiro, Institutos Madrileño de Estudios Avanzados IMDEA, Oncoclínicas
Lung Cancer
05/24
03/25
Ozeki
EMERALD, NCT05001737 / 2021-001577-24: Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Active, not recruiting
3
41
Europe, Canada, Japan, US, RoW
Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO)
Swedish Orphan Biovitrum
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
06/24
09/25
Shimizu
EMERALD, NCT05001737 / 2021-001577-24: Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Active, not recruiting
3
41
Europe, Canada, Japan, US, RoW
Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO)
Swedish Orphan Biovitrum
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
06/24
09/25
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
Lopes, Joao
NCT05693129: Pediatric Patients Aged 1 to 6 Years with APDS

Recruiting
3
15
Europe, Japan, US
Leniolisib
Pharming Technologies B.V., CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
APDS
09/25
02/26
Ohno, Kazuchika
DISCOVARY, NCT05694819: Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma

Active, not recruiting
2
56
Japan
Darolutamide, Goserelin
National Cancer Center Hospital East, Bayer Yakuhin, Ltd.
Salivary Gland Cancer
08/24
02/26
Shibata, Moe
NCT05438407 / 2022-001624-14: Pediatric Patients Aged 4 to 11 Years With APDS

Active, not recruiting
3
15
Europe, Japan, US
Leniolisib
Pharming Technologies B.V., CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
APDS
07/25
12/25
NCT05693129: Pediatric Patients Aged 1 to 6 Years with APDS

Recruiting
3
15
Europe, Japan, US
Leniolisib
Pharming Technologies B.V., CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
APDS
09/25
02/26

Download Options